Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: mallory36 who wrote (7046)	3/25/1998 4:56:00 PM
From: hoffy	Respond to of 8116

>>>I have been in cyto 3 years. i can tell all the new commers that when ever we have a run we always fall back! Do a historical chart and look. The volume is wow for this maybe this time we will do different. I really hope so i've down enough to pay my house off!!<<< I have been in Cyto for over a year now since about 4 and have suffered some. I do agree that in the past it has always backed off any gains. Guess that is why we were at 1 1/4 the other day. However this time the volume is huge. Over 1 millio yesterday and close to 2 million today. Also during the day it started to back up again but at the close it ended very strong gaining an 1/8th in the last half hour. I think something must be up. I have no idea what but from the volume someone besides the little guy is buying into this thing. Hopefully this run can take us over the 3 level, maybe even close to 4. I'm just waiting for some news. that will get this thing flying

To: mallory36 who wrote (7046)	3/25/1998 4:59:00 PM
From: John Mattessich	Read Replies (1) \| Respond to of 8116

Check it out : biz.yahoo.com The highlight of the article is shown below : In addition, Richard D. Klausner, M.D., Director of the National Cancer Institute, will discuss ''Challenges and Opportunities in Cancer Research: The NCI Director's View.'' Breakthrough Discoveries Other notable discoveries in cancer research that will be presented at scientific sessions throughout the meeting include: -- Identification of a serum hormone that can be used to assess prostate cancer risk better than the standard PSA test